The Healthcare Distribution Management Association on Tuesday honored 10 pharmaceutical and consumer product manufacturers through the presentation of its annual Distribution Management Awards for Notable Achievements in Healthcare, or DIANA. The winners were announced Monday evening at the Association’s 2012 Business and Leadership Conference in San Antonio, Texas.
When one of Amylin Pharmaceuticals' diabetes drugs is used with mealtime insulin, both Type 1 and Type 2 diabetes patients maintain blood sugar in the normal glucose range on a daily basis, according to two analyses presented at the 72nd Scientific Sessions of the American Diabetes Association.
An investigational insulin being developed by Novo Nordisk significantly reduced the rate of hypoglycemia at night in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented at the 72nd Scientific Sessions of the American Diabetes Association.
An experimental drug made by Bayer HealthCare extended the length of time that patients with gastrointestinal tumors survived without their disease getting worse, according to results of a late-stage clinical trial released Monday.
Five pharmacy organizations on Thursday wrote Congress in opposition of an amendment to the Food and Drug Administration Safety Innovation Act due to its potential to delay patients' timely relief from chronic pain while increasing drug costs.
The House of Representatives on Wednesday passed legislation that reauthorizes the Food and Drug Administration’s prescription drug user fee programs that are scheduled to expire in September. H.R. 5651 passed the House by a vote of 387 to 5.
The slow economy, cost cutting and lower use of services by patients looking to save money will combine to cause healthcare spending to grow at a "historically" low rate in 2013, according to a new report released Thursday.
As the Food and Drug Administration works to finalize draft guidance related to the development of biosimilar products, pharmacy groups recently weighed in with recommendations to facilitate the entry of lower-cost products into the biologic and specialty pharmaceutical markets.